JP2024540271A5 - - Google Patents

Info

Publication number
JP2024540271A5
JP2024540271A5 JP2024526502A JP2024526502A JP2024540271A5 JP 2024540271 A5 JP2024540271 A5 JP 2024540271A5 JP 2024526502 A JP2024526502 A JP 2024526502A JP 2024526502 A JP2024526502 A JP 2024526502A JP 2024540271 A5 JP2024540271 A5 JP 2024540271A5
Authority
JP
Japan
Prior art keywords
sequence
antisense oligonucleotide
compound number
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/080478 external-priority patent/WO2023078883A1/en
Publication of JP2024540271A publication Critical patent/JP2024540271A/ja
Publication of JP2024540271A5 publication Critical patent/JP2024540271A5/ja
Pending legal-status Critical Current

Links

JP2024526502A 2021-11-03 2022-11-02 アポリポタンパク質ｅ４発現を調節するためのオリゴヌクレオチド Pending JP2024540271A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21206278 2021-11-03
EP21206278.0 2021-11-03
PCT/EP2022/080478 WO2023078883A1 (en) 2021-11-03 2022-11-02 Oligonucleotides for modulating apolipoprotein e4 expression

Publications (2)

Publication Number Publication Date
JP2024540271A JP2024540271A (ja) 2024-10-31
JP2024540271A5 true JP2024540271A5 (https=) 2025-11-10

Family

ID=78516663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526502A Pending JP2024540271A (ja) 2021-11-03 2022-11-02 アポリポタンパク質ｅ４発現を調節するためのオリゴヌクレオチド

Country Status (5)

Country Link
US (1) US20240294915A1 (https=)
EP (1) EP4426833A1 (https=)
JP (1) JP2024540271A (https=)
CN (1) CN118318042A (https=)
WO (1) WO2023078883A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025159427A1 (ko) * 2024-01-26 2025-07-31 서울대학교산학협력단 신규한 apoe 안티센스 올리고뉴클레오타이드 및 이의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
WO2004046160A2 (en) 2002-11-18 2004-06-03 Santaris Pharma A/S Amino-lna, thio-lna and alpha-l-oxy-ln
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2526295T5 (es) 2006-10-18 2021-05-04 Ionis Pharmaceuticals Inc Compuestos antisentido
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
CA2935426C (en) 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2018178994A1 (en) * 2017-03-29 2018-10-04 Ramot At Tel-Aviv University Ltd. Compositions and methods specifically targeting the apolipoprotein e4 (apoe4) and uses thereof in apoe4 associated conditions
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス，インコーポレーテッド 神経変性疾患のための遺伝子治療
CN110257510A (zh) * 2019-08-06 2019-09-20 江苏贝格尔生物医药有限公司 一种检测apoe基因多态性的引物和探针及试剂盒
CN114269925A (zh) * 2020-02-28 2022-04-01 尔知渃米斯股份有限公司 Apoe4 rna特异性反式剪接核酶及其用途
IL297702A (en) * 2020-04-27 2022-12-01 Alnylam Pharmaceuticals Inc Apolipoprotein e (apoe) irna agent compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2010505432A5 (https=)
JP4383720B2 (ja) オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
US5631135A (en) Oligonucleotide N3'→P5' phosphoramidates: hybridization and nuclease resistance properties
JP6384845B2 (ja) アンチセンス核酸
AU682576B2 (en) Nucleosides and oligonucleotides having 2'-ether groups
JP4012579B2 (ja) ２’−エーテル基を有するヌクレオシド及びオリゴヌクレオチド
IL135000A (en) Locked nucleoside analogues contain nucleic acid compounds that contain them
Imanishi et al. BNAs: novel nucleic acid analogs with a bridged sugar moiety
De Mesmaeker et al. Comparison of rigid and flexible backbones in antisense oligonucleotides
CN106255697B (zh) 磷保护基团及其制备方法和用途
WO2014175974A2 (en) Artificial nucleic acids
JP2013525330A5 (https=)
JP2021505129A5 (https=)
RU2020121752A (ru) Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты
CN109952378A (zh) 经修饰的寡核苷酸及使用方法
JP2015532097A5 (https=)
JP2024540271A5 (https=)
JP3675847B2 (ja) ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法
JPWO2022064908A5 (https=)
JP2020521491A5 (https=)
US8680262B2 (en) Purification of oligonucleotides
WO2006030906A1 (ja) ヌクレオシド類似体またはその塩
JP2004175708A (ja) 二環性ナフチリジンヌクレオシド
EP4553080A1 (en) Nucleoside derivatives as antiviral agents against coronaviruses
JP7813254B2 (ja) Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド